06. Late adverse events occurred in 14% and 5.3%, respectively, p=0.44, with no severe adverse event. Curative resection rates were 67% and 63% for adenocarcinomas of the esophagus and the gastric cardia, respectively, p=0.89.

ESD is a safe treatment for T1 adenocarcinomas of the esophagogastric junction, curative in two thirds of the patients, in tumors arising from the esophagus or from the stomach. ESD should be considered for the routine resection of esophageal adenocarcinomas.

ESD is a safe treatment for T1 adenocarcinomas of the esophagogastric junction, curative in two thirds of the patients, in tumors arising from the esophagus or from the stomach. ESD should be considered for the routine resection of esophageal adenocarcinomas.

The impact of sarcopenia in patients undergoing simultaneous liver and kidney transplantation (SLKT) has not been fully delineated. The aim of this single-centre-cohort-study was to evaluate the impact of sarcopenia on the clinical outcomes.

Between 2003 and 2018, 79 patients underwent SLKT. Sarcopenia was assessed via the total psoas muscle area (TPA) at the level of the 3rd. lumbar vertebra. Sarcopenia threshold was TPA < 1460 mm

(women) and <1560 mm

(men). We identified post-operative biliary, vascular and digestive complications. Survival analysis was performed by the Kaplan Meier method (log-rank test).

We included 43/79 SLKT recipients (56%male, median age of 58 [53-63] years). The prevalence of cirrhosis was 74% (n = 32) with median MELD-score of 21 (20-22) and that of polycystic-liver-disease was 26% (n = 11). End-stage-renal-disease of unknown origin was 36.2% (n = 12). Dialysis before transplantation was performed in 54,8% (n = 23) of patients. The median TPA was 1138 (926-1510) mm

, and sarcopenia was detected in 72% of patients (n = 31). No difference in patient or death-censored graft-survival between sarcopenic and non-sarcopenic groups at 1 year was reported. Also, no differences at 6-months’ post-transplant-complication-free and infection-free-survival rates were found.

In this cohort of patients, no differences were observed in patients, grafts, complications or infection-free survival between sarcopenic or no sarcopenic SLKT patients. Future multi-centre studies are needed to validate and extend the generalisability of these findings.

In this cohort of patients, no differences were observed in patients, grafts, complications or infection-free survival between sarcopenic or no sarcopenic SLKT patients. Future multi-centre studies are needed to validate and extend the generalisability of these findings.

To confirm the value of PVT1 as a prognostic marker both in tumour tissue and serum of patients with esophageal cancer and clarify the mechanism.

This study analyzed data obtained from 76 patients who were surgically treated from January 1, 2015, to December 31, 2016, and received a pathological diagnosis of ESCC. selleck kinase inhibitor PVT1 levels in tumour tissue and serum were detected by qRT-PCR. Patient data were extracted from medical records, and follow-up evaluations were performed. The roles of PVT1 in proliferation, migration and invasion were by CCK-8 and Transwell in stable knockdown PVT1 cell lines. Signal pathways PVT1 promotes esophageal cancer were detected by qRT-PCR and western blot.

PVT1 was overexpression in esophageal cancer tissues and high levels of PVT1 were correlated with lymphatic metastasis, high TNM stage and postoperative metastasis. High levels of PVT1 in tissues were correlated with worse metastasis-free survival (MFS) (HR 2.578, 95% CI 1.369-4.853). High level of PVT1 in serum was correlated with postoperative metastasis. High levels of PVT1 in serum were correlated with worse overall survival (OS) (HR 2.124, 95% CI 1.078-4.186) and worse MFS (HR 2.786, 95% CI 1.557-4.985). Knockdown of PVT1 decreased the cell proliferation, migration and invasion abilities of esophageal cancer cell lines. The expression of ZEB1 was significantly downregulated, and the expression of E-cadherin was increased by the knockdown of PVT1. Knockdown of miR-128 restored the altered proliferation, migration and invasion and the expression of ZEB1 and E-cadherin caused by knockdown of PVT1.

High levels of PVT1 in serum were correlated with postoperative metastasis and a poor prognosis. PVT1 promoted ESCC progression via the miR-128/ZEB1/E-cadherin axis.

High levels of PVT1 in serum were correlated with postoperative metastasis and a poor prognosis. PVT1 promoted ESCC progression via the miR-128/ZEB1/E-cadherin axis.

Nonalcoholic steatohepatitis (NASH) patients are at a high risk of developing venous thromboembolism, with a high rate of morbidity and mortality. The role of neutrophil extracellular traps (NETs) in procoagulant activity (PCA) in patients with NASH remains unclear. Our study aimed to investigate the formation of NETs in NASH patients stimulated by specific pro-inflammatory factors. Moreover, we evaluated the pivotal role of NETs in the induction of hypercoagulability in NASH and the interaction between NETs and endothelial injury.

The levels of the NETs biomarkers were evaluated in the plasma samples of 27 NASH patients and 18 healthy subjects. The formation of NETs was visualized using immunofluorescence microscopy. The PCA of the NETs was assessed using coagulation time, purified coagulation complex, and fibrin formation assays. Confocal microscopy was further used to evaluate the interactions between the NETs and HUVECs.

The levels of NETs markers in the plasma of NASH patients were significantly higher than healthy controls. NETs derived from NASH enhanced thrombin and fibrin formation and significantly reduced CT (p<0.05). The mixture of IL-6 and TNF-α triggered the NETs release in the plasma rather than them alone. Additionally, the NETs exerted cytotoxic effects on the endothelial cells, converting them to a procoagulant and pro-inflammatory phenotype, and DNase I could reverse these effects.

Our results revealed the primary role of NETs in promoting the hypercoagulable state in NASH patients. Methods that prevent the formation of NETs may be a novel approach for the prevention and treatment of NASH.

Our results revealed the primary role of NETs in promoting the hypercoagulable state in NASH patients. Methods that prevent the formation of NETs may be a novel approach for the prevention and treatment of NASH.